- Dr. George W. Sledge, Jr., M.D., is Professor and Chief of Medical Oncology at the Stanford University Medical Center
- Dr. Sledge brings decades of experience and leadership in cancer research and drug development to Tessa
Tessa Therapeutics, a clinical-stage immunotherapy company focused on autologous and off-the-shelf, allogeneic therapies for cancer patients, today announced that Dr. George W. Sledge, Jr., M.D., Professor and Chief of Medical Oncology at Stanford University Medical Center, will join Tessa's Board of Directors as an independent director, effective 2 January 2019.
This appointment marks another significant step to strengthen Tessa's industry expertise, as the company builds and advances its portfolio of therapies to treat more cancer patients worldwide.
"I would like to warmly welcome Dr. Sledge to the Tessa team," said Tessa Therapeutics co-founder and CEO, Mr. Andrew Khoo. "He brings with him a wealth of experience, having spent over two decades developing novel biologic treatments for breast cancer as well as directing a Phase III study on the use of paclitaxel to treat advanced breast cancer. His leadership in cancer research and within the oncology community will be invaluable in supporting the Board of Directors and management team. Tessa is truly privileged to be able to add this outstanding leader to our Company."
